Pancreatic Cancer Research

ResearcherSun Yat-sen UniversityActive in the last 2 years

Yize Mao

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0001-6481-5725; OpenAlex author ID A5101701562. Sources: OpenAlex.

Their work

Papers
14 (first author 8, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
35
Papers, trials and grants by year

2018: 1 paper · 2019: 1 paper · 2020: 3 papers · 2021: none · 2022: 3 papers · 2023: 1 paper · 2024: none · 2025: 3 papers · 2026: 2 papers

Papers 14

  1. Deep Learning Predicts Imminent Tumor Progression in Advanced Pancreatic Adenocarcinoma Using Serial CT Scans During Chemotherapy. First author DOI 10.1002/mco2.70870↗
  2. A STING signaling relay from tumor cells to macrophages mediates the improved efficacy of combination chemotherapy in pancreatic cancer. First author DOI 10.1186/s12929-026-01226-1↗
  3. Neutrophil-to-apolipoprotein A1 ratio predicted the efficiency of chemotherapy in advanced pancreatic cancer. First author DOI 10.1016/j.pan.2025.03.004↗
  4. Trends in pancreatic cancer incidence, prevalence, and survival outcomes by histological subtypes: a retrospective cohort study. First author DOI 10.1093/gastro/goaf030↗
  5. Noninvasive Computed Tomography-Based Quantification of Tumor Fibrosis Predicts Pancreatic Cancer Response to Gemcitabine/Nab-Paclitaxel. First author DOI 10.34133/research.0937↗
  6. Serum Amyloid a Predicts Prognosis and Chemotherapy Efficacy in Patients with Advanced Pancreatic Cancer. Co-author DOI 10.2147/jir.s404900↗
  7. The enhanced cell cycle related to the response to adjuvant therapy in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.ygeno.2021.11.036↗
  8. Multimodal data analysis reveals that pancreatobiliary-type ampullary adenocarcinoma resembles pancreatic adenocarcinoma and differs from cholangiocarcinoma. First author DOI 10.1186/s12967-022-03473-w↗
  9. Identifying Outcomes of Patients With Advanced Pancreatic Adenocarcinoma and RECIST Stable Disease Using Radiomics Analysis. First author DOI 10.1200/po.21.00362↗
  10. Oxidative stress induces monocyte-to-myofibroblast transdifferentiation through p38 in pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/ctm2.41↗
  11. Induced CD10 expression during monocyte-to-macrophage differentiation identifies a unique subset of macrophages in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.bbrc.2020.02.042↗
  12. SYPL1 Inhibits Apoptosis in Pancreatic Ductal Adenocarcinoma via Suppression of ROS-Induced ERK Activation. Co-author DOI 10.3389/fonc.2020.01482↗
  13. A feasible CT feature to differentiate focal-type autoimmune pancreatitis from pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/cam4.2526↗
  14. Intravoxel incoherent motion magnetic resonance imaging for differentiating metastatic and non-metastatic lymph nodes in pancreatic ductal adenocarcinoma. First author DOI 10.1007/s00330-017-5259-0↗

Closest collaborators

The 25 strongest of 35 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Shengping Li · 9 shared papers, 2018–2026 · strength 1.20
  2. Qiuxia Yang · 4 shared papers, 2025–2026 · strength 1.00
  3. Sen Lei · 2 shared papers, 2025 · strength 0.61
  4. Qiuxia Yang · 4 shared papers, 2019–2023 · strength 0.59
  5. Lizhi Liu · 3 shared papers, 2022–2026 · strength 0.57
  6. Jun Cheng · 3 shared papers, 2022–2026 · strength 0.56
  7. Rong Zhang · 3 shared papers, 2018–2025 · strength 0.52
  8. Zehui Yao · 2 shared papers, 2023–2026 · strength 0.44
  9. Xiaoping Yi · 2 shared papers, 2025–2026 · strength 0.42
  10. Chaobin He · 4 shared papers, 2019–2020 · strength 0.41
  11. Jun Wang · 1 shared paper, 2025 · strength 0.33
  12. Xin Huang · 3 shared papers, 2020 · strength 0.31
  13. Shuxin Sun · 3 shared papers, 2020 · strength 0.31
  14. Liqin Li · 2 shared papers, 2022 · strength 0.29
  15. Honglu Ding · 1 shared paper, 2026 · strength 0.25
  16. Xiaojun Xia · 1 shared paper, 2026 · strength 0.25
  17. Jing Xue · 1 shared paper, 2026 · strength 0.25
  18. Jun Wang · 2 shared papers, 2020 · strength 0.21
  19. Yunda Song · 2 shared papers, 2020 · strength 0.20
  20. Honglu Ding · 1 shared paper, 2023 · strength 0.19
  21. Dailei Qin · 1 shared paper, 2023 · strength 0.19
  22. Ruiqi L. Wang · 1 shared paper, 2023 · strength 0.19
  23. Xuejun Gong · 1 shared paper, 2025 · strength 0.19
  24. Ningning Niu · 1 shared paper, 2025 · strength 0.19
  25. Peng Luo · 1 shared paper, 2025 · strength 0.19

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.